← Back to Clinical Trials
Recruiting NCT07181317

NCT07181317 WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction: Cohort Follow up

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07181317
Status Recruiting
Phase
Sponsor French Cardiology Society
Condition Myocardial Infarction, Acute
Study Type OBSERVATIONAL
Enrollment 314 participants
Start Date 2025-11-25
Primary Completion 2029-09-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 60 Years
Study Type OBSERVATIONAL
Interventions
QuestionnairesMajor events

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 314 participants in total. It began in 2025-11-25 with a primary completion date of 2029-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients.

Eligibility Criteria

All patients who participated in the WAMIF study (research registration number with the French Ministry of Health : 2015-A01263-46 / Protocol registration with Clinical Trials NCT03073447) and wish to continue follow-up in the study.

Contact & Investigator

Central Contact

Tessa BERGOT, MSc

✉ tessa.bergot@sfcardio.fr

📞 +33144907033

Principal Investigator

Stéphane MANZO SILBERMAN, MD

PRINCIPAL INVESTIGATOR

Hôpital de la Pitié-Salpêtrière, APHP

Frequently Asked Questions

Who can join the NCT07181317 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 60 Years, studying Myocardial Infarction, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07181317 currently recruiting?

Yes, NCT07181317 is actively recruiting participants. Contact the research team at tessa.bergot@sfcardio.fr for enrollment information.

Where is the NCT07181317 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT07181317 clinical trial?

NCT07181317 is sponsored by French Cardiology Society. The principal investigator is Stéphane MANZO SILBERMAN, MD at Hôpital de la Pitié-Salpêtrière, APHP. The trial plans to enroll 314 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology